The CDC voted in favor of including this drug on its list of hepatitis B products. Large players volume suggests this is a big deal. Dynavax Technologies announced that the
Gilead Sciences looks like a good oversold, candle over candle setup.
Synergy Pharmaceuticals has a PDUFA ruling coming within the next couple of days. The Twiggs Money Flow has started to run ahead of the FDA announcement.
Reata Pharmaceuticals stock has heavy insider buying after positive phase 2 trial results on its drug bardoxolone.
Xencor stock has a deep pipeline of both collaboration programs as well as in-house pipeline advancements.
Sorrento Therapeutics stock has a buy signal on the Twiggs Money Flow while the stock consolidates. This is one of my favorite divergence patterns to trade.
Sarepta Therapeutics could get European marketing approval for Exondys 51 at any time which will boost sales. Meanwhile, the company has great growth and is advancing other drugs through its pipeline.
BeiGene stock has large players volume exploding higher. The company reported eye-popping earnings and revenue beats this week.
Deciphera Pharmaceuticals will likely be pumped by the IPO underwriters soon now that the quiet period has ended.
Intercept Pharmaceuticals stock sold off on an FDA warning letter at the end of the quarter. Since, large players volume has been rising while the stock has formed a basing pattern.